Dasatinib

目录号:S1021 别名: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib是一种新型有效的多靶点抑制剂,作用于AblSrc和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。

规格 价格 库存 购买数量  
RMB 1142.64 现货
RMB 1224.97 现货
RMB 3039.93 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献72篇:

客户使用该产品的13个实验数据:

  • Antitumor activity (A)and body weight (B) relationship for BLU-285 and dasatinib in a P815 KIT D814Y mastocytoma allograft model.

    Science, 2017, 9(414), doi: 10.1126/scitranslmed.aao1690. Dasatinib purchased from Selleck.

    Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

  • Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述 Dasatinib是一种新型有效的多靶点抑制剂,作用于AblSrc和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。
靶点
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
体外研究

在抑制表达野生型Bcr-Abl或全部Bcr-Abl突变型(除了T315I)的Ba/F3增殖时,Dasatinib效果比Imatinib高很多。与Imatinib相比,Dasatinib呈2倍指数增长效力(约325倍)。Dasatinib有效抑制野生型Abl 激酶和全部突变型(除了T315I)。Dasatinib 直接靶向作用于野生型和突变型Abl激酶域,且抑制自磷酸化和底物磷酸化,这种作用存在浓度依赖性。Dasatinib作用于表达野生型 Bcr-Abl的细胞时,效果比Imatinib高325倍多。[1] TgE骨髓细胞菌落百分数从未处理孔的100% 降低到Dasatinib处理孔的4.12%。 有 Dasatinib存在时, WT 和TgE骨髓细胞形成的菌落百分数明显不同。LMP2A的表达可促进 B 淋巴细胞存活和增殖,而Dasatinib通过靶向作用于Lyn 和/或c-Abl 激酶可抑制以上存活和增殖。[2] Dasatinib 处理一系列甲状腺癌细胞,抑制Src信号, 降低生长速度,使细胞周期停滞,且诱导凋亡。使用剂量不断增加的 Dasatinib (0.019 μM 到 1.25 μM) 处理C643, TPC1, BCPAP, 和 SW1736 细胞3天,抑制50%细胞生长,然而抑制K1细胞系生长则需更高浓度Dasatinib。使用10 nM 或50 nM Dasatinib 处理BCPAP,SW1736 和 K1 细胞,导致G1期细胞提高9-22%,而S期细胞百分数则降低7-18%。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NEHzNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\mfFczKGh? MX;EUXNQ NUC0ZZJ1UUN3ME2wMlAxODB5IN88US=> MnHHNVc6PTZyOEC=
K562 MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDENpE4OiCq NHrpN|VFVVOR NHnLR3FKSzVyPUCuNFAyKM7:TR?= NYDYU3ZLOTd7NU[wPFA>
M07e MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWG3NkBp NFnZ[nBFVVOR M1i5c2lEPTB;MD6wNFEzKM7:TR?= NV3zZ29COTd7NU[wPFA>
ALL3 MVLDfZRwfG:6aXOgRZN{[Xl? M3\WPVAvOc7:TR?= NUjGfmxHPzJiaB?= M3:1b2ROW09? MoC4TWM2OD1yLkCwNFQh|ryP MWWxPVg5QTV2MB?=
CML NH\oNW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7oV5Q4OjBibXnu M2fGVGROW09? MXLJR|UxRTBwMECxJO69VQ>? MUWxPVIyQTBzNh?=
BA/F3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PxO|czKGh? M{P2VWROW09? NIfNTVNKSzVyPU[uOVg6KM7:TR?= MYGyN|A5QDZ2NB?=
BA/F3 NUflfZppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rYNlczKGh? MYPEUXNQ M1zpcGlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJGJkei2DYnygUVM2OVRibYX0ZY51KHerdHigTWM2OCCxZjCwMlAxODh|zszN MnjxNlMxQDh4NES=
BA/F3 NUXNOGdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:0O|IhcA>? M2DRTmROW09? M1\pdWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJJdqdGRidInw[UBD[3JvQXLsJJdqfGhiSVO1NEBw\iByLkCwOFXPxE1? NH2zUpMzOzB6OE[0OC=>
BA/F3 NVjSZ|NyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkW5O|IhcA>? NYrVXI5uTE2VTx?= M4jBS2lv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJGJkei2DYnygWFMyPUlibYX0ZY51KHerdHigTWM2OCCxZjCxMlcyPM7:TR?= MVWyN|A5QDZ2NB?=
BA/F3 NUnhb2J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrhXVZMPzJiaB?= M{nnVGROW09? MoHHTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTjR6NmOgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNFnPxE1? MWOyN|MxOTdyMx?=
BA/F3 NVe5[Gg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLCO|IhcA>? NUf2VYRqTE2VTx?= MWjJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOjV3SzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECzNu69VQ>? M1Tq[VI{OzBzN{Cz
BA/F3 NG\HRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFGzO5o4OiCq MmTPSG1UVw>? M1z2Nmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEd{NUDFJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFUy|ryP NVL2Vm5UOjN|MEG3NFM>
BA/F3 NID2UYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnOO|IhcA>? MXLEUXNQ NGn4b|ZKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCTMkWyTEBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA5|ryP NHXNOnMzOzNyMUewNy=>
BA/F3 NILxbZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPTNmY4OiCq MYjEUXNQ M36xTGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV|NUnWJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFE{|ryP MkezNlM{ODF5MEO=
BA/F3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K2UFczKGh? NXu1XWdrTE2VTx?= MknBTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCEQ2KtRWJNKGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAxNjByMUpOwG0> M4T5OFI{OzBzN{Cz
BA/F3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYO3NkBp MnztSG1UVw>? M1PifGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFl{NUPIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFI{|ryP MnH6NlM{ODF5MEO=
BA/F3 MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWC3NkBp NV;0NmY{TE2VTx?= NFLZdZBKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCWM{G1TUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIEOuOu69VQ>? M2m0fFI{OzBzN{Cz
BA/F3 NEfBXotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G3V|czKGh? M2XuTGROW09? NUX0UZZ{UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOi53zszN NHzQTmMzOzNyMUewNy=>
T cell NXzUSVAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fsc|czKGh? MlHuSG1UVw>? M1vW[mlvcGmkaYTzJIFvfGliQ1SzMUBidmRiYX70bUBETDJ6LXnu[JVk\WRiVDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECz{txO MoCxNVcyPTR3MUK=
WiDr NYrHOIF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnOO|IhcA>? MYHEUXNQ NXvLfZF5UUN3ME2wMlA2OiEQvF2= MYexOVYyPTVzMh?=
PC3 M4\oVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7UO|IhcA>? NYj2ZWU{TE2VTx?= M2HjT2lEPTB;MD6wNFk1KM7:TR?= MoDnNVU3OTV3MUK=
MDA-MB-231 NUP0NJBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrIeJZuPzJiaB?= NV;MV3p{TE2VTx?= MULJR|UxRTBwMEGyJO69VQ>? MYSxOVYyPTVzMh?=
Hs578T MYjDfZRwfG:6aXOgRZN{[Xl? MXO3NkBp NYrRdol7TE2VTx?= NHz0NGlIUTVyPUCuNFMh|ryP NUO2SJFEOjRyMUWzNlc>
HMEC NXXmZWhIS3m2b4TvfIlkKEG|c3H5 MnroO|IhcA>? MlnQSG1UVw>? M2HpXGdKPTB;MT64JO69VQ>? MXOyOFAyPTN{Nx?=
DU145 M3T6NmN6fG:2b4jpZ{BCe3OjeR?= MkfwO|IhcA>? NHe0UYhFVVOR NIDpdGdIUTVyPUCuNVYh|ryP MV6yOFAyPTN{Nx?=
U251 MV7DfZRwfG:6aXOgRZN{[Xl? NHz1TZM4OiCq MUTEUXNQ MkHpS2k2OD1{LkixJO69VQ>? MnuwNlQxOTV|Mke=
NCI60 MlzoR5l1d3SxeHnjJGF{e2G7 NXzsS5N2PzJiaB?= NH\CTVdFVVOR NIrj[pdIUTVyPUWuO{DPxE1? MW[yOFAyPTN{Nx?=
MALME-3M MoXaR5l1d3SxeHnjJGF{e2G7 NULKcFVsPzJiaB?= MY\EUXNQ NIjq[nhIUTVyPU[uOlEh|ryP MnHVNlQxOTV|Mke=
KM12 NI\Y[3ZEgXSxdH;4bYMhSXO|YYm= MYi3NkBp MYnEUXNQ MW\HTVUxRTdwNESg{txO M3n0bFI1ODF3M{K3
SW620 MmTrR5l1d3SxeHnjJGF{e2G7 M1\ib|czKGh? MUjEUXNQ Mo\XS2k2OD16LkSzJO69VQ>? NF3rcGkzPDBzNUOyOy=>
RXF 393NL MXjDfZRwfG:6aXOgRZN{[Xl? MXW0JIRigXN? NH3TW2NFVVOR NX;ZcnljUUN3ME2wMlAzOTdizszN MWKyN|I2OzB5NB?=
LXFA 983L Mn\4R5l1d3SxeHnjJGF{e2G7 Mnm5OEBl[Xm| MXXEUXNQ M2LuTmlEPTB;MD6wOVY2KM7:TR?= M{DnO|I{OjV|MEe0
PRXF DU145 NXX6N4N3S3m2b4TvfIlkKEG|c3H5 M{DrS|Qh\GG7cx?= NHTB[2RFVVOR NG\WSGpKSzVyPUCuNFYzOyEQvF2= MnPlNlMzPTNyN{S=
PAXF 1657L NXfy[VUyS3m2b4TvfIlkKEG|c3H5 NFzqVXc1KGSjeYO= M4Tw[mROW09? MkjOTWM2OD1yLkGyNUDPxE1? MYSyN|I2OzB5NB?=
CXF 1103L MXzDfZRwfG:6aXOgRZN{[Xl? MoHEOEBl[Xm| NF3DdWZFVVOR Ml\FTWM2OD12LkO2JO69VQ>? M4CyUlI{OjV|MEe0
GXF251L M13MUGN6fG:2b4jpZ{BCe3OjeR?= MXm0JIRigXN? MWXEUXNQ NYDIcZJUUUN3ME2yMlI2KM7:TR?= NF7qWXczOzJ3M{C3OC=>
NCI-H23 MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LKelczKGh? M4DhfWROW09? M2nkZWlEPTB;Mj6yO{DPxE1? MYCyN|UzOTB{MB?=
HCT116 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M122OFczKGh? M1HWN2ROW09? M{DPUmlEPTB;Mj6zJO69VQ>? NEDVeGIzOzV{MUCyNC=>
MCF7 NInWTGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXsZ|E4OiCq NX\JeHdITE2VTx?= MknjTWM2OD1{LkW3JO69VQ>? MkLlNlM2OjFyMkC=
NCI-H460 M4W4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2mx[lczKGh? MWHEUXNQ NInrWWlKSzVyPUiuPVkh|ryP NEXpb|UzOzV{MUCyNC=>
DLD1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrJUW04OiCq MW\EUXNQ NHrkNpdKSzVyPUSuOkDPxE1? MXOyN|U3Pzl4MB?=
NCI-H661 NEW5WpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HLOVczKGh? NGTU[2ZFVVOR M17xUmlEPTB;Nz64JO69VQ>? NUHlRZg3OjN3Nke5OlA>
A549 NH6xUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUW3NkBp M1nYSGROW09? NGfUUpBKSzVyPUiuNkDPxE1? NUDBeldCOjN3Nke5OlA>
U937 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDhSnh3PzJiaB?= NHrnNVdFVVOR MYXJR|UxRTF{LkKg{txO NGfVclAzOzV4N{m2NC=>
HEK293 M{HwR2Z2dmO2aX;uJGF{e2G7 M1v3b|ExyqEQvF2= NF;oVXFFVVOR MoHGTY5lfWOnczDibY5lcW6pIHHm[olvcXS7IITvJIh2dWGwIH\1cIwudGWwZ4ToJGhqey22YXfn[YQhVXm2MTDrbY5ie2ViZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC5aYToJGlEPTBib3[gNE4xPjQQvF2= NWG4SWdJOjJ5N{C2NVA>
HUVEC NFz1SGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTRNE4yPcLizszN M4\qXlczKGh? M3vReWROW09? MWjJcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHH0JFAvOTVidV2= MVOyNlg2Ozl7Mx?=
HUVEC MVLGeY5kfGmxbjDBd5NigQ>? MlOwNVXDqM7:TR?= MlfIO|IhcA>? NX3vR4JsTE2VTx?= M3n4WGlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO MVOyNlg2Ozl7Mx?=
Plasmodium falciparum NYP5c3VuTnWwY4Tpc44hSXO|YYm= M{\lbVExyqEQvF2= MkLyNVUhdWmw MUfEUXNQ MVLJcohq[mm2czDQcIF{dW:maYXtJIZidGOrcHHyeY0heHKxbHnm[ZJifGmxbjDifUBqdmirYnn0bY5oKHSqZTDGeY5kfGmxbjDv[kBR\kOGUFuxJJBzd3SnaX6ge4l1cCCLQ{WwJI9nKDFwMUhOwG0> NVLDT2tROjR3NUCzN|A>
PC3 Mk[0SpVv[3Srb36gRZN{[Xl? NFrKVZExNjFizszN MUC1JIg> NHfK[4JFVVOR NH7ZNWZKdmirYnn0d{BpfW2jbjDQR|Mh[2WubDDh[Ihme2mxbjDheEAyODBibl2= Mm\nNVk1PjJ7N{W=
DU145 NXzW[mkzTnWwY4Tpc44hSXO|YYm= M2TDOVAvOSEQvF2= MlXqOUBp MlzZSG1UVw>? NWPTVY5JUW6qaXLpeJMhcHWvYX6gSHUyPDViY3XscEBi\Ginc3nvckBifCBzMECgcm0> NYXROVdzOTl2NkK5O|U>
PC3 NWr6bnZYU2mwYYPlJGF{e2G7 MX6wMlEh|ryP NEG5XlM2KGh? NH\weYJFVVOR M4nKWmlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2= M2W1[FE6PDZ{OUe1
DU145 MWDLbY5ie2ViQYPzZZk> MWewMlEh|ryP MmPGOUBp M2[5OWROW09? MU\Jcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2= NYT6WWJDOTl2NkK5O|U>
PC3 Mnj4T4lv[XOnIFHzd4F6 MWewMlEh|ryP NYHnbIJWPSCq NIe1[2NFVVOR MW\Jcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0> Mn22NVk1PjJ7N{W=
DU145 M{LLSWtqdmG|ZTDBd5NigQ>? NWC5T257OC5zIN88US=> NXPEZpUxPSCq MnfNSG1UVw>? MVHJcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>? M3zYe|E6PDZ{OUe1
Huh7 NIjFe4JCdnSrdnnyZYwhSXO|YYm= MVuyMlUh|ryP NWW4NGRwPCCmYYnz NIPEUZZFVVOR NGnVPJNKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGi3bXHuJGh2cDdiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2= MlvsNVc{PjB4N{[=
C6/36 NUGwNJBCSW62aY\pdoFtKEG|c3H5 NXTaeJdOOi53IN88US=> Mlr5OEBl[Xm| MkG5SG1UVw>? M1fVd2lvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQh[XOrYX6geIlo\XJibX;zdZVqfG9iQ{[vN|Yh[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? Mm\oNVc{PjB4N{[=
U937 MX;GeY5kfGmxbjDBd5NigQ>? NV6yb3JOOSEQvF2= MV[xJIg> NH3DNJBFVVOR NVf1NolsWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO= MlPvNVc3QDRyOUm=
U937 NYPpRnMxTnWwY4Tpc44hSXO|YYm= NIH6XWcyKM7:TR?= M4Lt[VEhcA>? M4XQcmROW09? NYfRUWZzWmWmdXPld{BNWFNvaX7keYNm\CCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN? MVyxO|Y5PDB7OR?=
murine mast cell NVTDeHgyTnWwY4Tpc44hSXO|YYm= MnPhNUDPxE1? M2LJblI1KGh? MWPEUXNQ M3v2SmlvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP NHrkV24yPzZ6NEC5PS=>
BV-173 NGL3SXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMECwNFAxOTB7IN88US=> M4PoOnNCVkeHUh?=
K-562 M{H4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMECwNFAxOjZ4IN88US=> M4rnbnNCVkeHUh?=
BL-70 NVW4fVU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTUTWM2OD1yLkCwNFAxODh{MjFOwG0> MXjTRW5ITVJ?
EM-2 MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr0co45UUN3ME2wMlAxODByMUC4JO69VQ>? MUPTRW5ITVJ?
LAMA-84 NYP4eolOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMECwNFA{OjFizszN NU\VZ5ZlW0GQR1XS
MEG-01 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi4W2VWUUN3ME2wMlAxODByOUig{txO MmmxV2FPT0WU
EoL-1-cell MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnUNohUUUN3ME2wMlAxODBzM{Gg{txO NIjxO|RUSU6JRWK=
CTV-1 NV;2SIRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nhU2lEPTB;MD6wNFAxPDB2IN88US=> NETKfmpUSU6JRWK=
TE-15 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX30cFBPUUN3ME2wMlAxPTh7IN88US=> NFXEfmVUSU6JRWK=
NOS-1 MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X5S2lEPTB;MD6wNFYyOyEQvF2= NVr1UFNGW0GQR1XS
D-336MG M3fm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGKyU5BKSzVyPUCuNFA3OyEQvF2= MYXTRW5ITVJ?
LB1047-RCC M4XGS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMEC5PFkh|ryP NHTCZphUSU6JRWK=
LB996-RCC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEC5PVEh|ryP M{jPc3NCVkeHUh?=
SW982 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\G[2lEPTB;MD6wNVEyPSEQvF2= MVPTRW5ITVJ?
TK10 MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMEGxO|Qh|ryP MlXPV2FPT0WU
A704 M{\1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW3TWM2OD1yLkCxOFkyKM7:TR?= MWXTRW5ITVJ?
TE-8 NUn2XoVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMEG1O|Yh|ryP M3Xld3NCVkeHUh?=
DOHH-2 NIDZT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHz6[oRKSzVyPUCuNFE4OTlizszN MXrTRW5ITVJ?
HOP-62 NHXJVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfxWldtUUN3ME2wMlAyQDN2IN88US=> MmO4V2FPT0WU
TE-12 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjac5ZtUUN3ME2wMlAyQDZzIN88US=> MVPTRW5ITVJ?
KGN MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEG5OFIh|ryP NI[3OYZUSU6JRWK=
NCI-H1648 NUTm[5NkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLKOIV3UUN3ME2wMlAzODFzIN88US=> MofDV2FPT0WU
OS-RC-2 NUfi[YdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMEKwN{DPxE1? Mof2V2FPT0WU
GB-1 NIrrXWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGn1T25KSzVyPUCuNFIyPTdizszN NYfHb5ZpW0GQR1XS
RXF393 M3vsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwMEKzOVch|ryP NGPUZ3pUSU6JRWK=
LC-2-ad NIP6cIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljLTWM2OD1yLkCyOVg3KM7:TR?= M17nSXNCVkeHUh?=
KS-1 NE\1OpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWW2VVNGUUN3ME2wMlAzPzNizszN M4q3OHNCVkeHUh?=
ETK-1 Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMEK4N|Ih|ryP NEXDNGRUSU6JRWK=
SW954 NUDmfGtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMEK5Nlch|ryP M{PZU3NCVkeHUh?=
Becker MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rKNWlEPTB;MD6wN|AxOyEQvF2= MXTTRW5ITVJ?
MZ1-PC NGHoTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMEOxNVkh|ryP NITI[XNUSU6JRWK=
ES6 NXjG[mEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzH[mc3UUN3ME2wMlA{OTl|IN88US=> MnzVV2FPT0WU
KURAMOCHI MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMEO0PFch|ryP MnK4V2FPT0WU
CGTH-W-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMEO1OFgh|ryP M4\LUnNCVkeHUh?=
VA-ES-BJ MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXFTWM2OD1yLkCzPVAzKM7:TR?= NFjNN3VUSU6JRWK=
LXF-289 NVPDbo9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfqSldKSzVyPUCuNFM6PTZizszN M{Lu[XNCVkeHUh?=
MPP-89 NEnWNGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHKOlhrUUN3ME2wMlA1ODR7IN88US=> MXPTRW5ITVJ?
SW872 MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLQTplpUUN3ME2wMlA1OTZzIN88US=> NHnBWHlUSU6JRWK=
SNB75 Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr5SHhKSzVyPUCuNFQ1OzVizszN NV3pRo5QW0GQR1XS
PSN1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwMES0O|Qh|ryP NIPLNXdUSU6JRWK=
LB831-BLC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Swe2lEPTB;MD6wOFYxQSEQvF2= MoLjV2FPT0WU
MFH-ino NHTwdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwMES3NlQh|ryP NVvnRmhPW0GQR1XS
TGBC24TKB M{f3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLEOYY1UUN3ME2wMlA1PzZzIN88US=> NGPWbo9USU6JRWK=
A388 NHrLSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHmzboJKSzVyPUCuNFUxQTVizszN M3Hk[XNCVkeHUh?=
BB30-HNC NVvpcpBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rJO2lEPTB;MD6wOVQ{PyEQvF2= MWjTRW5ITVJ?
GI-ME-N MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3oXJRKSzVyPUCuNFYyOThizszN NHnKcGhUSU6JRWK=
TGBC1TKB NEjxbJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O2bWlEPTB;MD6wOlE3PCEQvF2= NGHiNJVUSU6JRWK=
TE-10 MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm4TWM2OD1yLkC2N|U4KM7:TR?= NXnndYpwW0GQR1XS
A498 NF3ZPI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMEeyPFQh|ryP M1\EeXNCVkeHUh?=
TE-11 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTJNmVKSzVyPUCuNFc5PThizszN NV\WS|d1W0GQR1XS
BB65-RCC Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\yeFJKSzVyPUCuNFgzOjdizszN MV3TRW5ITVJ?
C2BBe1 NHHwV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DkVGlEPTB;MD6wPFMxQCEQvF2= NIS2W2hUSU6JRWK=
NCI-H747 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTyTWM2OD1yLkC4N|YzKM7:TR?= M3jLW3NCVkeHUh?=
IST-MES1 NHvzOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLYTWM2OD1yLkC4OVUzKM7:TR?= Ml[3V2FPT0WU
KALS-1 M3zMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPwZ29KSzVyPUCuNFk1QSEQvF2= NEfrRnBUSU6JRWK=
GCIY MlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\PUZdGUUN3ME2wMlA6PjV4IN88US=> NWfEbmxlW0GQR1XS
RL95-2 MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkH3TWM2OD1yLkGwN|gh|ryP Mn20V2FPT0WU
TE-1 NILnRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\kVY5KSzVyPUCuNVA2PCEQvF2= NGmzeHJUSU6JRWK=
NCI-H1355 NWjnfWlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHJboxwUUN3ME2wMlEyODJ6IN88US=> NXfSWmlzW0GQR1XS
SW962 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMUGyPVIh|ryP MWjTRW5ITVJ?
KLE NIr1TZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMUGzNVch|ryP MYnTRW5ITVJ?
MC116 NIjDOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPnSHFqUUN3ME2wMlEyPDFizszN NHi4SHdUSU6JRWK=
NMC-G1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HtXGlEPTB;MD6xNVYxPiEQvF2= NHXKfoRUSU6JRWK=
KU812 NV3SfopXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkiyTWM2OD1yLkGxPFg{KM7:TR?= MVnTRW5ITVJ?
COLO-829 NXnZSoxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\KTWM2OD1yLkGyNlE{KM7:TR?= MVTTRW5ITVJ?
NTERA-S-cl-D1 MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMUKyPFMh|ryP NUSz[Hc{W0GQR1XS
IST-MEL1 MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnpeXlRUUN3ME2wMlE{PDVizszN MX\TRW5ITVJ?
MLMA NHTQU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLkTWM2OD1yLkG0NFMzKM7:TR?= NVzY[WZWW0GQR1XS
LS-123 MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjnTWM2OD1yLkG0NFY1KM7:TR?= M2DmUXNCVkeHUh?=
LB2518-MEL NWPjSZBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMUSxOlIh|ryP M1vOW3NCVkeHUh?=
NB69 NELUT|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLW[2JEUUN3ME2wMlE1PDN4IN88US=> NHuxN|NUSU6JRWK=
8-MG-BA MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LxeWlEPTB;MD6xOVQ2QCEQvF2= NF7TOY1USU6JRWK=
K5 M1e2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDXTWM2OD1yLkG2OFg6KM7:TR?= NU\jdJJtW0GQR1XS
KINGS-1 NX7weJlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwMU[2OlYh|ryP M1PicHNCVkeHUh?=
SF268 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzGTWM2OD1yLkG3OFA1KM7:TR?= NYrwc|dEW0GQR1XS
PF-382 MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLXVm9PUUN3ME2wMlE4Pjd6IN88US=> NF7CWI9USU6JRWK=
SH-4 NHS0U49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrLTWM2OD1yLkG4OFE{KM7:TR?= MUXTRW5ITVJ?
NALM-6 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwMUmyPVUh|ryP Mnj5V2FPT0WU
CP66-MEL MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLyTWM2OD1yLkG5OVMyKM7:TR?= MnXqV2FPT0WU
697 NYruXnBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\BTWM2OD1yLkG5PVg4KM7:TR?= NFrS[3RUSU6JRWK=
CP67-MEL Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMkC0PFgh|ryP M1:5SnNCVkeHUh?=
DSH1 M2L0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjwcYVkUUN3ME2wMlI1ODBzIN88US=> NVX1S5Q4W0GQR1XS
HCE-4 MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH5SopKSzVyPUCuNlY1OzlizszN M3;hUHNCVkeHUh?=
MZ2-MEL M4H2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwMki1N|ch|ryP M{nFeXNCVkeHUh?=
BL-41 NWX1NZdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPSTXJKSzVyPUCuNlkyOjNizszN NGG5UZFUSU6JRWK=
HUTU-80 M{TNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr5c|IzUUN3ME2wMlMyPDJizszN M4fkbXNCVkeHUh?=
LOXIMVI MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX4bGE6UUN3ME2wMlMyPTB|IN88US=> NUSz[md3W0GQR1XS
no-10 Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPMRm9KSzVyPUCuN|E6OzFizszN NGKxRWZUSU6JRWK=
KARPAS-422 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP2TWM2OD1yLkOzPVk4KM7:TR?= NIPiNFFUSU6JRWK=
SW684 NXjHOXlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[0Z4pKSzVyPUCuN|Q6QCEQvF2= MW\TRW5ITVJ?
SF126 MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW0TWM2OD1yLkO1OFEh|ryP NX3HTZlSW0GQR1XS
D-263MG NXn5e4F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwM{[yNlQh|ryP MoD2V2FPT0WU
OVCAR-4 MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnz5TWM2OD1yLkO3OFM{KM7:TR?= MX7TRW5ITVJ?
BB49-HNC NXz1[21vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf5[|VKSzVyPUCuN|g2QTlizszN NHLmW2VUSU6JRWK=
ONS-76 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTVTWM2OD1yLkSyPVUyKM7:TR?= M4\CO3NCVkeHUh?=
MZ7-mel Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\qTWM2OD1yLkS3PVEyKM7:TR?= MXrTRW5ITVJ?
RCC10RGB NEnLS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPpTWM2OD1yLkS5NVEh|ryP NEKzVItUSU6JRWK=
BOKU MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPNfnUyUUN3ME2wMlQ6OTN|IN88US=> NULTNXI1W0GQR1XS
no-11 M1vyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTyNHBKSzVyPUCuOVAzOjhizszN M1nDPHNCVkeHUh?=
IST-SL2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XH[mlEPTB;MD61NFMxOiEQvF2= NXjsfFRQW0GQR1XS
RKO NXXJfFQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nzPWlEPTB;MD61Nlk3PiEQvF2= M1\0eHNCVkeHUh?=
HT-144 NGXwdpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[xTWpKSzVyPUCuOVM3ODlizszN MnP2V2FPT0WU
NCI-H446 NYPFeXVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHmTWM2OD1yLk[yO|Yh|ryP NUHiZlUyW0GQR1XS
QIMR-WIL NIDFOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwN{C2Nlkh|ryP Mn;uV2FPT0WU
MHH-PREB-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3H3XGlEPTB;MD63OFQ3QSEQvF2= Mmn4V2FPT0WU
EW-16 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DBW2lEPTB;MD63OlE4QCEQvF2= M1qxRXNCVkeHUh?=
EW-24 NUfSXZpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP6TWM2OD1yLke4NVY2KM7:TR?= M{\ib3NCVkeHUh?=
LB373-MEL-D MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;LXHpiUUN3ME2wMlgzPTB6IN88US=> NHzQSXJUSU6JRWK=
TE-9 MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MornTWM2OD1yLki3OVMzKM7:TR?= NHvFdWxUSU6JRWK=
A3-KAW MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7iXYhKSzVyPUCuPVg1PTJizszN MWXTRW5ITVJ?
A101D M3zGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\aTpVyUUN3ME2xMlA{ODR|IN88US=> Mo\IV2FPT0WU
OCUB-M M4rXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjvdFhKSzVyPUGuNFQ1OTJizszN NVHrToNtW0GQR1XS
ES4 MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnrTWM2OD1zLkC1NVQ2KM7:TR?= NH62[FZUSU6JRWK=
TE-6 NHHYRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFwMkGyNlYh|ryP NX;penhCW0GQR1XS
D-502MG M1HYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:zOVJ{UUN3ME2xMlI{Ozd4IN88US=> Mnn6V2FPT0WU
KNS-42 NF36TmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XufWlEPTB;MT6yOFQyOiEQvF2= MoLNV2FPT0WU
SNU-C2B NEnCdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrkTWM2OD1zLkOwOVg6KM7:TR?= NUPISJFyW0GQR1XS
NCI-H1838 NGfJV|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn3bVFKSzVyPUGuN|A4OzNizszN MUXTRW5ITVJ?
NKM-1 NUK1UW1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFwM{C4OVkh|ryP NHL4WIdUSU6JRWK=
GI-1 NWPGSoZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\lR2lEPTB;MT6zOlIzKM7:TR?= MY\TRW5ITVJ?
NB5 MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHTSpFKSzVyPUGuN|k5OjdizszN MWrTRW5ITVJ?
CAS-1 M{LPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFwNEC5PVIh|ryP NV\LZYNXW0GQR1XS
HCE-T M4HnfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjqTWM2OD1zLkW2O|E1KM7:TR?= MWrTRW5ITVJ?
SBC-1 MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrueI4zUUN3ME2xMlU4QTh2IN88US=> NVLG[GdrW0GQR1XS
JiyoyeP-2003 NH;EXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Hn[mlEPTB;MT63N|Q3PiEQvF2= MUPTRW5ITVJ?
TE-5 M1fzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLCTWM2OD1zLke5NVM6KM7:TR?= NE[1WlhUSU6JRWK=
CAN NVTkUFBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwOEKyOVIh|ryP M{\JXXNCVkeHUh?=
SK-UT-1 Mmq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXzXoZKSzVyPUKuNVY3QTNizszN NGjlTG5USU6JRWK=
JVM-2 NX\4dmdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHodmtKSzVyPUKuN|YzQDRizszN Mn2zV2FPT0WU
LB771-HNC M4rNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LlPWlEPTB;Mj61O|U2OSEQvF2= MXTTRW5ITVJ?
NCCIT NW\nZlN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHi3cGZKSzVyPUKuPFY3OTZizszN NVXlcXY6W0GQR1XS
NCI-H2126 Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj3[IJKSzVyPUKuPFc2PTJizszN M{\3enNCVkeHUh?=
Calu-6 NH7vVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\W[GdGUUN3ME2zMlA2PzRzIN88US=> NUPyS4dVW0GQR1XS
SK-LMS-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTNwMUG4PFYh|ryP M{nD[nNCVkeHUh?=
ARH-77 NH;4UW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrMTWM2OD1|LkS2PVE2KM7:TR?= NETVVW9USU6JRWK=
NB17 NXj6Z3Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTNwNkO4OFch|ryP M3\MfXNCVkeHUh?=
A253 M1PxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDRV|BtUUN3ME2zMlc{OjR4IN88US=> M1TKdnNCVkeHUh?=
OPM-2 M2nHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXsSJBKSzVyPUSuNlc3QDVizszN M1zYV3NCVkeHUh?=
MV-4-11 MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfaNmtKSzVyPUSuN|Y1PTRizszN NX7kUJlwW0GQR1XS
SR MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLMU2hIUUN3ME20MlQ6QTV2IN88US=> NF\0UHpUSU6JRWK=
KG-1 MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmewTWM2OD12Lk[wPFQ2KM7:TR?= NFv4ZnVUSU6JRWK=
OCI-AML2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nZdGlEPTB;NT64OlE2PCEQvF2= MnrqV2FPT0WU
D-247MG M4Dvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHxTIRKSzVyPU[uNVI2OTlizszN NFPEcnlUSU6JRWK=
DJM-1 NH;BW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof0TWM2OD14LkS4OVU5KM7:TR?= NXThdoR6W0GQR1XS
RPMI-6666 NX76VYNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnzO|NKSzVyPUeuNlcxPjdizszN NEfTcG1USU6JRWK=
KARPAS-45 NFPiU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF36[YpKSzVyPUeuOVE3PzFizszN M17COXNCVkeHUh?=
LP-1 NG\Fe|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n6WmlEPTB;Nz61OFc5OiEQvF2= NH;ON3lUSU6JRWK=
RS4-11 M3Xwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4KwOmlEPTB;Nz62OVc5PyEQvF2= MUTTRW5ITVJ?
DU-4475 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILCTolKSzVyPUiuNlE3PTJizszN MnHrV2FPT0WU
MONO-MAC-6 Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXy[XRuUUN3ME24MlI4ODZ4IN88US=> MV3TRW5ITVJ?
NCI-SNU-16 M3viXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHjdYFKSzVyPUiuOVYyOjhizszN NH3pVIRUSU6JRWK=
SJSA-1 NX;K[FZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvCTWM2OD16LkeyPFA2KM7:TR?= NHfLbZZUSU6JRWK=
MMAC-SF MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRThwN{mzNFch|ryP NVHaNHI4W0GQR1XS
SK-NEP-1 NX7HN5JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPoTWM2OD16Lki5NVU2KM7:TR?= M4jpeHNCVkeHUh?=
J-RT3-T3-5 NITTfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HWcGlEPTB;OD65OlUzQSEQvF2= M1rTOHNCVkeHUh?=
SKM-1 M{jON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPVeY9KSzVyPUmuNFE4OzRizszN M1LjZnNCVkeHUh?=
LB2241-RCC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWO4dYVvUUN3ME25MlAzODF{IN88US=> M1H1Z3NCVkeHUh?=
SIG-M5 NHLTTYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H1NGlEPTB;OT6wNlQ6OyEQvF2= MYTTRW5ITVJ?
EVSA-T M1:xXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTlwMke3PVMh|ryP NI\ZN5BUSU6JRWK=
GT3TKB M3r3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDrUmhKSzVyPUmuN|U2PDZizszN MWTTRW5ITVJ?
NB6 M3fKWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonGTWM2OD17LkmyNlU6KM7:TR?= MofyV2FPT0WU
EHEB M3;YeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\hTWM2OD1zMD6wOlU3KM7:TR?= NECx[INUSU6JRWK=
HEL NF;tW|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnydplKSzVyPUGwMlQ4PzZizszN NUfBWXljW0GQR1XS
ALL-PO MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7xTWM2OD1zMD63PVM5KM7:TR?= Mnz0V2FPT0WU
TGW M2f5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfMTWM2OD1zMT6yPFI5KM7:TR?= M4fnNnNCVkeHUh?=
BC-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVviXlZxUUN3ME2xNk4yOTN6IN88US=> M2rudHNCVkeHUh?=
IA-LM MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fQN2lEPTB;MUKuOFQ1PSEQvF2= M2TGb3NCVkeHUh?=
UACC-257 M{fOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\4TWM2OD1zMj65NVk5KM7:TR?= NU[4b2VWW0GQR1XS
KP-N-YS M172VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW3boREUUN3ME2xNk46Ojh|IN88US=> NIDVPGVUSU6JRWK=
Raji NV\WUHpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmGwTWM2OD1zMz63OFk4KM7:TR?= Mk\VV2FPT0WU
SF539 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j1dWlEPTB;MUOuPFU2PyEQvF2= MYXTRW5ITVJ?
DMS-153 NGW3WoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF2LkCwNlgh|ryP MXvTRW5ITVJ?
L-540 M3HYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXNXphoUUN3ME2xOU4xPjd{IN88US=> NFLMfYhUSU6JRWK=
MN-60 M3PxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{P1VmlEPTB;MUWuNVk4QSEQvF2= MULTRW5ITVJ?
RPMI-8866 NUW5VWVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7PdWRKSzVyPUG3MlQ1PTRizszN MkPwV2FPT0WU
NCI-H510A NEXEVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoeyTWM2OD1zOT6zPVc{KM7:TR?= NW\IcVM3W0GQR1XS
NB13 M{[xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W3d2lEPTB;MUmuOFg4PyEQvF2= MmjCV2FPT0WU
HAL-01 NILYb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF7Lke1OFMh|ryP MV\TRW5ITVJ?
NCI-H720 NH3BUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DReWlEPTB;MkCuNlc{OyEQvF2= NETmeHpUSU6JRWK=
REH MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDSVItKSzVyPUKwMlY{PTdizszN MnvZV2FPT0WU
KNS-81-FD NYXPSYl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTJ|LkG0OkDPxE1? NHrROXlUSU6JRWK=
HC-1 NUP6R|BHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJ2LkW1OVEh|ryP NHq1XllUSU6JRWK=
NCI-H2141 MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoP4TWM2OD1{ND63O|U1KM7:TR?= M3;5e3NCVkeHUh?=
MOLT-4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zCR2lEPTB;Mk[uOlc2OyEQvF2= MX\TRW5ITVJ?
OMC-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G4OmlEPTB;MkeuNVQzOiEQvF2= NXjNfpFFW0GQR1XS
LC-1F M2XyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXNTWM2OD1{Nz6zNlQ2KM7:TR?= MYnTRW5ITVJ?
NCI-H1304 MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nhUWlEPTB;MkiuNVYzQCEQvF2= NFXuT3ZUSU6JRWK=
BC-1 M1nIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInDcXdKSzVyPUK4MlY2OSEQvF2= NIWyTVFUSU6JRWK=
NCI-H64 NXe0RmR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzJXXNKSzVyPUK5MlYzPTNizszN NVjh[5RHW0GQR1XS
MOLT-16 NX34W5ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj1eZBsUUN3ME2yPU43Ojl{IN88US=> MVLTRW5ITVJ?
U-87-MG NIP6Z3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPkTWM2OD1|MD63OlYh|ryP MXvTRW5ITVJ?
GAK M{X6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrTW5BZUUN3ME2zNU4zPjh4IN88US=> MlnMV2FPT0WU
ES8 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTN{LkGyOVIh|ryP MX7TRW5ITVJ?
HCC1599 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTN{LkOzNlUh|ryP MV\TRW5ITVJ?
EB-3 NVfadWM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHCSJpKSzVyPUO0MlMyOTdizszN M2\TcnNCVkeHUh?=
HCC1187 NVrCW49ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzwTWM2OD1|NT64NFUzKM7:TR?= MnXIV2FPT0WU
SK-PN-DW NGjleGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTN4LkG5OFMh|ryP NHj0dnBUSU6JRWK=
JVM-3 NUPBVnVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvsUWZKUUN3ME2zO{4zOzN6IN88US=> M123TnNCVkeHUh?=
HCC2157 NX;GVolOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTN5Lkm5OFYh|ryP NEC1O2RUSU6JRWK=
A4-Fuk M2DMWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXRO2p2UUN3ME2zPE4yODB7IN88US=> MWPTRW5ITVJ?
COR-L279 MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX21b49mUUN3ME20NE4zQDVzIN88US=> MUnTRW5ITVJ?
DEL Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTRzLkmwPFYh|ryP MUPTRW5ITVJ?
NCI-H1395 NUS2emdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTR{LkCxOlMh|ryP M4rHVnNCVkeHUh?=
MHH-NB-11 NH\5R|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPlenhKSzVyPUSzMlA5OThizszN NEH2UnVUSU6JRWK=
NCI-H2107 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrrU2VKSzVyPUSzMlQ5PDZizszN MWfTRW5ITVJ?
NEC8 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjoPHpjUUN3ME20OE4{OzZizszN MlS1V2FPT0WU
COLO-684 M2TqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3VTWM2OD12Nj6yNlU5KM7:TR?= MV7TRW5ITVJ?
LS-411N MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX4e|lZUUN3ME20PE41PzR6IN88US=> NX\NUpBHW0GQR1XS

... Click to View More Cell Line Experimental Data

体内研究 Dasatinib 作用于LMP2A/MYC 双转基因小鼠,可逆转脾肿大。Dasatinib 作用于TgE小鼠 抑制表达LMP2A 的骨髓B 细胞形成的菌落,且使脾脏变小。使用Dasatinib处理Tg6/λ-MYC 小鼠,与对照组相比,脾脏质量明显降低。Dasatinib 作用于LMP2A/MYC 双转基因小鼠,抑制淋巴结肿大。Dasatinib作用于嫁接LMP2A/MYC双转基因小鼠肿瘤细胞的Rag1KO小鼠,可逆转脾肿大。Dasatinib 作用于表达LMP2A的B 淋巴细胞瘤,抑制Lyn磷酸化。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

激酶自磷酸化分析:

使用野生型和突变型谷胱甘肽S-转移酶(GST)-Abl融合蛋白 (c-Abl氨基酸220-498位) 进行激酶实验。从谷胱甘肽琼脂糖珠中释放GST-Abl融合蛋白,ATP浓度为5 μM。在用于激酶自磷酸化和体外肽底物磷酸化实验前, 用LAR酪氨酸磷酸酶处理GST-Abl 激酶域融合蛋白。在 30oC下温育1小时后,加入1 mM 钒酸钠,激活LAR磷酸酶。进行免疫印迹分析,比较未处理的GST-Abl激酶和去磷酸化的GST-Abl激酶,使用磷酸化的特点抗体4G10来 确认酪氨酸残基完全去磷酸化(>95%),使用c-Abl抗体 CST 2862 来确认GST-Abl激酶的平衡负载。实验测定IC50值时所用Dasatinib浓度为0 nM到32 nM。Dasatinib作用于突变型T315I时浓度达到 1,000 nM。在体外肽底物磷酸化实验中使用相同抑制剂浓度。作用于GST-Src激酶和 GST-Lyn激酶的三种抑制剂的浓度范围相同。
细胞实验: [1]
+ 展开
  • Cell lines: Ba/F3细胞系
  • Concentrations: 0 nM-32 nM
  • Incubation Time: 72小时
  • Method: Ba/F3 细胞系重复培养三份,然后与浓度逐渐升高的 Dasatinib 温育72小时。通过MTS活性实验测定细胞增殖。IC50值和IC90值取自三组独立实验的平均值。Dasatinib作用的IC50值和IC90值为0 nM 到32 nM 。Dasatinib 作用于突变型T315I时所需浓度达到200 nM。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: EμLMP2A(TgE 和Tg6品种),MYC (λ-MYC), 和LMP2A/λ-MYC双转基因小鼠(Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据